Investigating genetic factors in pediatric brain tumors with specific mutations
Official title: Genetic dependencies in KIAA1549-BRAF rearranged pediatric low-grade gliomas
Funded at Broad Institute, INC. · NIH-11055113 · Data updated 2026-11-12
This study is looking at a specific type of brain tumor in kids and how a certain gene change affects its growth, with the goal of finding better treatments that are easier on young patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $143,788 |
| NIH project number | 1K99CA290163-01A1 |
| Project ID | NIH-11055113 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with pediatric low-grade gliomas that have the KIAA1549-BRAF genetic mutation.
✕Less likely to help
Patients without the KIAA1549-BRAF mutation or those with other types of brain tumors may not benefit from this research.
What this research studies
This research focuses on pediatric low-grade gliomas, a type of brain tumor that often has a specific genetic mutation involving the KIAA1549 and BRAF genes. The study aims to understand how this mutation affects tumor growth and survival, particularly looking at the role of the POMT complex, which is essential for the health of cells with this mutation. By exploring these genetic dependencies, the research seeks to develop new treatment strategies that could minimize side effects and improve outcomes for affected children. Patients may be involved in trials that test new therapies targeting these genetic pathways.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for children with specific brain tumors.
How similar studies have gone: Previous research has shown promise in targeting genetic mutations in tumors, suggesting that this approach could yield beneficial results.
Where this research is happening
-
Broad Institute, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Misek, Sean Alexander — Broad Institute, INC.
- Study coordinator: Misek, Sean Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.